Avantor, Inc.
15.08-0.03 (-0.2%)
Oct 28, 4:00:02 PM EDT · NYSE · AVTR · USD
Key Stats
Market Cap
10.28BP/E (TTM)
14.93Basic EPS (TTM)
1.01Dividend Yield
0%Recent Filings
8-K
Avantor refinances debt, boosts liquidity
Avantor bolstered its liquidity on October 9, 2025, by amending its credit agreement to secure $1.4 billion in revolving commitments maturing in 2030, a €400 million Euro Term A loan due 2030, and a €550 million Euro Term B-6 loan due 2032, while terminating its $300 million A/R facility after repaying $208 million outstanding. Proceeds refinanced existing debt, including the full €650 million redemption of 2.625% Senior Notes completed by October 10. This extends maturities and frees up operational funding. Yet covenants limit flexibility amid market shifts.
8-K
Avantor chairman steps down
Avantor, Inc. announced on October 10, 2025, that Jonathan Peacock will step down as chairman and board member on December 31, 2025, with no disagreements on company matters. Current board member Gregory L. Summe will assume the chairman role starting January 1, 2026. This leadership transition ensures continuity at the top. Smooth handover.
8-K
Avantor appoints Lucier to board
Avantor elected Gregory Lucier to its Board of Directors, effective October 3, 2025, adding deep life sciences expertise from his CEO roles at Corza Medical, NuVasive, and Life Technologies. Lucier, who scaled Invitrogen to over $4 billion in sales before its sale to Thermo Fisher, will receive prorated standard non-employee director pay: $95,000 annual cash retainer and $210,000 in restricted stock units vesting in one year. This bolsters Avantor's growth strategy in lab solutions and bioscience production. Forward-looking statements highlight potential value creation amid market risks.
8-K
Ligner joins Avantor Board
Avantor elected Emmanuel Ligner to its Board of Directors on August 7, 2025, effective August 18, filling a vacant seat as he prepares to assume the President and CEO role. This dual appointment aligns leadership without extra Board compensation. Ligner's selection stems from the Nominating and Governance Committee's recommendation. No related transactions demand disclosure.
8-K
Q2 sales flat organically
Avantor reported Q2 2025 net sales of $1.68 billion, down 1% year-over-year with flat organic revenue, while net income fell to $65 million from $93 million. Adjusted EBITDA held at $280 million, but margins slipped to 16.6% amid restructuring costs and segment challenges in Laboratory Solutions. Bioscience Production grew 3% reported. Leadership shifts soon: Emmanuel Ligner succeeds Michael Stubblefield as CEO on August 18. Execution remains disciplined.
IPO
Employees
Sector
Industry
A
Agilent Technologies, Inc.
145.85-0.74
ATR
AptarGroup, Inc.
128.10-0.68
ATRC
AtriCure, Inc.
36.45-0.02
AVNT
Avient Corporation
32.60-0.05
AZTA
Azenta, Inc.
31.36-0.51
BDX
Becton, Dickinson and Company
184.21-2.83
BIO
Bio-Rad Laboratories, Inc.
330.42-5.70
RSCF
Reflect Scientific, Inc.
0.05+0.00
SOAGY
Sartorius AG
55.07-0.56
WST
West Pharmaceutical Services, I
283.49-3.73